Martin F. Fromm, MD, MD

Martin worked on the role of drug transporters in modulating antiarrhythmic drug actions. His studies were the first to demonstrate that inhibition of P-glycoprotein function by quinidine is responsible for the well-recognized, but until then, poorly characterized quinidine-digoxin interaction. Martin is currently Chair of the Department of Clinical Pharmacology and Clinical Toxicology at the Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University, Erlangen-Nuremberg, Germany.